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“Join us in making the voice of rare diseases heard” is
the slogan of Rare Disease Day 2016, a special day estab-
lished by EURORDIS (http://www.rarediseaseday.org/).
It takes place on the last day of February each year since
2008, to raise awareness amongst the general public and
decision-makers about rare diseases and their impact on
patients’ lives. This has also been one of the goals of
Orphanet Journal of Rare Diseases (OJRD), since its
inception 10 years ago.
This year’s slogan appeals to everyone who can make a
difference but it appeals to us healthcare professionals
and researchers first. We have a duty to create greater
awareness for each of the thousands of rare diseases
identified so far, by publishing the scarce data to which
we have access.
Orphanet Journal of Rare Diseases (OJRD) is commit-
ted during this commemorative year and beyond, to
publishing review articles on specific rare diseases with
the goal of expanding knowledge among health profes-
sionals and caregivers. Such articles are highly valued by
patients and caregivers, especially for very rare diseases.
Summarising the available published literature is a major
effort requiring experience, an asset of only a few profes-
sionals around the world. It is also a time-consuming
exercise which is often postponed by many experts who
are already overloaded. OJRD invites the rare disease
community of experts to write up such reviews as the
necessary step to make possible the dissemination of
knowledge on diseases which are never taught at med-
ical school. According to the Orphanet database, which
systematically collects such articles provided that the
copyright holders give permission to provide free access,
there are currently 400 review articles published in peer-
review journals, covering 1132 rare diseases. There are
also 625 gene reviews documenting 1289 rare genetic
diseases. Additional effort is needed to update these
reviews and produce new ones.
Review articles are necessary and useful, but there is
another type of compilation of scarce knowledge which
can make an even more direct difference for the pa-
tients. It is the publication of clinical guidelines designed
to support the decision-making process in patient care.
This is the only way to champion improvements in qual-
ity and consistency in healthcare. The methodology for
establishing such clinical guidelines is standardised in
many countries by Health Technology Assessment
(HTA) agencies. Clinical guidelines encode evidence-
based recommendations, a feature hardly accessible in
the case of most rare diseases as there are very few pub-
lished articles reviewing the outcome of different proto-
cols. Most clinical guidelines can only be defined due to
the gathering of expert opinions which is considered the
lowest possible level of evidence, but is still much better
that nothing. The Orphanet database provides access to
100 clinical guidelines covering 470 rare diseases, a very
low number indeed. They were produced either by
learned societies, charities, by disease-specific consor-
tiums, or HTA agencies. They are very costly to produce
due to the intensity and complicated nature of the
process that has to be respected. They have to ensure
that they not only reflect the gathered evidence, but also
fit within the healthcare systems as they define health-
care pathways. It is the reason why only a few of them
can be considered to be “International” clinical guide-
lines, most of them being quite specific to a country or a
region. OJRD is inviting funders to support the develop-
ment of clinical guidelines and will support their
publication.
For some rare diseases it is also indispensable to pro-
vide emergency guidelines for pre-hospital emergency
care as well as for hospital emergency care, as some
interventions can be decisive, negatively or positively, in
the recovery of the patient. These are even more difficultCorrespondence: segolene.ayme@inserm.fr
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to produce and translate into recommendations which
can be widely applicable. Currently the Orphanet
database gives access to 44 emergency guidelines for
85 rare diseases (http://www.orpha.net/consor/cgi-bin/
Disease_Emergency.php?lng=EN). They were produced
by French reference centres and patient organisations,
edited by Orphanet, peer-reviewed by emergency
practitioners, and then translated into English.
Patients suffering from a rare disease are more
likely to need inpatient care, surgery and anaesthesia.
Perioperative complications may occur in this setting,
especially if the medical team lacks specific know-
ledge of the disease. Reliable information on orphan
diseases is essential to avoid preventable disease-
related complications such as unexpectedly difficult
intubations, electrolytic imbalances, or adverse reac-
tions or interactions of medication. The German Society
of Anaesthesiology and Intensive Care developed
OrphanAnaesthesia, (http://www.orphananesthesia.eu/
en/home.html) an anaesthesiology-related database on
orphan diseases which now contains over 30 guide-
lines published in German and English (written and
peer reviewed by experts). Projects like these need
more volunteers to contribute towards the production
of potentially life-saving recommendations.
OJRD is also committed to contributing to the debate
on appropriate policies for ensuring optimal care for
patients and giving a voice to patients whose insight into
the issues is a core asset. To this aim, OJRD and Findacure
(http://www.findacure.org.uk/) joined efforts earlier this
year to provide an opportunity for medical students to
write an essay on a facet of rare diseases. One selected
essay, which was published as a Letter to the Editor [1] in
OJRD, is the clearest invitation to the rare disease com-
munity of experts to take the necessary time to dissemin-
ate their knowledge as soon as possible. OJRD intends to
provide a forum for these experts and their patients’
voices, for decades to come.
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